New Stock News | Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) Submits Application to Hong Kong Stock Exchange, BGM0504 has the greatest global potential in its class.

According to the Hong Kong Stock Exchange's disclosure on May 18th, Brightgene Bio-Medical Technology Co., Ltd. (688166.SH) submitted its listing application to the Hong Kong Stock Exchange main board, with Huatai International as its exclusive sponsor. The prospectus shows that Brightgene Bio-Medical Technology Co., Ltd. is a global pharmaceutical company with a commercial network covering over 40 countries and regions. With multidisciplinary expertise and leading research and development capabilities in the industry, the company has established a diversified product portfolio covering active pharmaceutical ingredients/intermediates, generic drugs, and innovative drugs. During the reporting period, the company's revenue mainly came from the sales of active pharmaceutical ingredients (substances that provide the expected therapeutic effect of a drug) and pharmaceutical intermediates (materials or compounds produced in the intermediate stages of drug manufacturing). By 2025, the global market share of the company's active pharmaceutical ingredients/intermediates products that have been mainly introduced to the market ranged from approximately 2.7% to 45.2%. According to data from Zhishi Consultancy, based on sales revenue in 2025, the company ranks among the top three global suppliers of penicillin-like active pharmaceutical ingredients/intermediates, and also generates revenue through the sale of formulated products. Formulated products refer to drugs that have been formulated into final dosage forms (such as injections, tablets, or inhalants) and are available for patient use, as well as providing research and production services to pharmaceutical companies using the company's internal capabilities, contributing a small portion of revenue during the reporting period. In terms of product portfolio, the company has successfully commercialized over 40 drugs, including 14 formulated products and 32 active pharmaceutical ingredients/intermediates, covering multiple therapeutic areas including infectious diseases, immune diseases, and oncological diseases. The company has eight main products on the market, each contributing over 5% of revenue during the reporting period, including micafungin sodium, oseltamivir phosphate, capsofungin acetate, amphotericin B, nifedipine, alerlisin hydrochloride, pimecrolimus, and davasatinib. The company is currently focusing on developing globally innovative proprietary therapies for metabolic diseases, as well as building a competitive line of inhalation drug-device combination products for respiratory diseases. With a solid foundation in high-barrier formulated and specialty active pharmaceutical ingredients, the company has successfully expanded into the field of innovative therapies, establishing a globally competitive product pipeline. As of now, the company has six major innovative drug candidates, with BGM0504 being the most representative. This GLP-1/GIP dual target agonist has the best global potential in its class and is suitable for treating type 2 diabetes (T2DM) and obesity/overweight. In terms of development progress, BGM0504 is currently one of the top three GLP-1/GIP dual target agonist candidate drugs in clinical trials globally, whether in injectable or oral dosage forms. Furthermore, in the field of respiratory diseases, the company is developing high-end inhalation candidate products with high barriers to entry, derived from advanced delivery systems of the drug-device combination technology platform. Combining direct sales and distribution channels, the company sells over 40 formulated products and active pharmaceutical ingredients/intermediates to more than 40 countries and regions, covering multiple therapeutic areas including infectious diseases, immune diseases, and oncological diseases, with major markets including mainland China, Europe, and North America. In the fiscal years 2023, 2024, and 2025, the company achieved revenue of approximately RMB 1.164 billion, RMB 1.255 billion, and RMB 1.198 billion respectively.